A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer

Clinical Trial ID NCT01130337

PubWeight™ 12.81^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01130337

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Trial watch: Chemotherapy with immunogenic cell death inducers.	Oncoimmunology	2012	1.33
2	HER2-positive gastric cancer.	Gastric Cancer	2013	1.32
3	Targeted therapy in gastroesophageal cancers: past, present and future.	Gastroenterol Rep (Oxf)	2015	0.85
4	Current status of novel agents in advanced gastroesophageal adenocarcinoma.	J Gastrointest Oncol	2015	0.83
5	Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer.	Therap Adv Gastroenterol	2012	0.83
6	Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies.	World J Gastroenterol	2013	0.82
7	New advances in targeted gastric cancer treatment.	World J Gastroenterol	2016	0.81
8	Recent advances in the HER2 targeted therapy of gastric cancer.	World J Clin Cases	2015	0.80
9	Personalized medicine in gastric cancer: Where are we and where are we going?	World J Gastroenterol	2016	0.79
10	Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy.	World J Gastroenterol	2014	0.78
11	Chemotherapy for operable gastric cancer: current perspectives.	Indian J Surg Oncol	2012	0.76
12	Chemotherapy: Perioperative therapy improves gastroesophageal cancer survival.	Nat Rev Clin Oncol	2011	0.75
13	Current adjuvant treatment modalities for gastric cancer: From history to the future.	World J Gastrointest Oncol	2016	0.75
14	Adjuvant therapy for gastric cancer: what have we learned since INT0116?	World J Gastroenterol	2015	0.75
15	Abstracts of New Developments in Hematology and Oncology in 2011. Guangzhou, China. December 25-26, 2011.	J Hematol Oncol	2012	0.75
16	Targeted therapy in gastric cancer.	Eur Surg	2016	0.75